Molecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata

Mycopathologia

Volumn 171, Issue 1, 2011, Pages 11-21

  Vandeputte, Patrick ^a,b   Pineau, Laurent ^a,e   Larcher, Gérald ^a   Noel, Thierry ^c   Brèthes, Daniel ^d   Chabasse, Dominique ^a,b   Bouchara, Jean Philippe ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c University Victor Segalen   (France)

^d Institut de Biochimie et Genetique Cellulaires   (France)

^e UNIVERSITÉ D'ANGERS   (France)

Author keywords

5 Fluorocytosine; Candida glabrata; FUR1, FCY1 and FCY2 genes; Resistance mechanisms

Indexed keywords

CANDIDA GLABRATA;

EID: 78650511059     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9342-1     Document Type: Article

References (34)

1. Krcmery V, Barnes AJ. Non-albicansCandida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002; 50: 243-60.
2. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect. 2007; 54: 521-9.
3. Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata: an emerging oral opportunistic pathogen. J Dent Res. 2007; 86: 204-15.
4. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, Tiraboschi N, Nagy E, Gibbs DL, the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6. 5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol. 2005; 43: 5848-59.
5. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002; 35: 622-30.
6. Kaur R, Domergue R, Zupancic ML, Cormack BP. A yeast by any other name: Candida glabrata and its interaction with the host. Curr Opin Microbiol. 2005; 8: 378-84.
7. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther. 2002; 24: 351-77.
8. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002; 2: 73-85.
9. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000; 46: 171-9.
10. Schönebeck J, Anséhn S. 5-Fluorocytosine resistance in Candida spp. and Torulopsis glabrata. Sabouraudia. 1973; 11: 10-20.
11. Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother. 1983; 23: 79-85.
12. Pujol C, Pfaller MA, Soll DR. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother. 2004; 48: 262-6.
13. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ. In vitro activities of 5-fluorocytosine against 8, 803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother. 2002; 46: 3518-21.
14. Fasoli M, Kerridge D. Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species. Ann N Y Acad Sci. 1988; 544: 260-3.
15. Papon N, Noël T, Florent M, Gibot-Leclerc S, Jean D, Chastin C, Villard J, Chapeland-Leclerc F. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob Agents Chemother. 2007; 51: 369-71.
16. Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother. 2004; 48: 2223-7.
17. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992; 15: 1003-18.
18. Polak A. 5-fluorocytosine-current status with special references to mode of action and drug resistance. Contrib Microbiol Immunol. 1977; 4: 158-67.
19. Hope WW, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother. 2004; 48: 4377-86.
20. Normark S, Schönebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother. 1972; 2: 114-21.
21. Fasoli M, Kerridge D. Uptake of pyrimidines and their derivatives into Candida glabrata and Candida albicans. J Gen Microbiol. 1990; 136: 1475-81.
22. Brun S, Bergès T, Poupard P, Vauzelle-Moreau C, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother. 2004; 48: 1788-96.
23. Vandeputte P, Tronchin G, Bergès T, Hennequin C, Chabasse D, Bouchara JP. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob Agents Chemother. 2007; 51: 982-90.
24. Vandeputte P, Larcher G, Bergès T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother. 2005; 49: 4608-15.
25. Noël T, François F, Paumard P, Chastin C, Brèthes D, Villard J. Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter. Antimicrob Agents Chemother. 2003; 47: 1275-84.
26. Rezusta A, Aspiroz C, Boekhout T, Cano JF, Theelen B, Guarro J, Rubio MC. Cholesterol dependent and amphotericin B resistant isolates of a Candida glabrata strain from an intensive care unit patient. Med Mycol. 2008; 46: 265-8.
27. Ko TP, Lin JJ, Hu CY, Hsu YH, Wang AH, Liaw SH. Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. J Biol Chem. 2003; 278: 19111-7.
28. Chevallier MR, Jund R, Lacroute F. Characterization of cytosine permeation in Saccharomyces cerevisiae. J Bacteriol. 1975; 122: 629-41.
29. Schmidt R, Manolson MF, Chevallier MR. Photoaffinity labeling and characterization of the cloned purine-cytosine transport system in Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 1984; 81: 6276-80.
30. Weber E, Rodriguez C, Chevallier MR, Jund R. The purine-cytosine permease gene of Saccharomyces cerevisiae: primary structure and deduced protein sequence of the FCY2 gene product. Mol Microbiol. 1990; 4: 585-96.
31. Dujon B, Sherman D, Fischer G, Durrens P, Casaregola S, Lafontaine I, De Montigny J, Marck C, Neuvéglise C, Talla E, Goffard N, Frangeul L, Aigle M, Anthouard V, Babour A, Barbe V, Barnay S, Blanchin S, Beckerich JM, Beyne E, Bleykasten C, Boisramé A, Boyer J, Cattolico L, Confanioleri F, De Daruvar A, Despons L, Fabre E, Fairhead C, Ferry-Dumazet H, Groppi A, Hantraye F, Hennequin C, Jauniaux N, Joyet P, Kachouri R, Kerrest A, Koszul R, Lemaire M, Lesur I, Ma L, Muller H, Nicaud JM, Nikolski M, Oztas S, Ozier-Kalogeropoulos O, Pellenz S, Potier S, Richard GF, Straub ML, Suleau A, Swennen D, Tekaia F, Wésolowski-Louvel M, Westhof E, Wirth B, Zeniou-Meyer M, Zivanovic I, Bolotin-Fukuhara M, Thierry A, Bouchier C, Caudron B, Scarpelli C, Gaillardin C, Weissenbach J, Wincker P, Souciet JL. Genome evolution in yeasts. Nature. 2004; 430: 35-44.
32. Sen Gupta S, Kerridge D, Chevallier MR. A purine permease in Candida glabrata. FEMS Microbiol Lett. 1995; 126: 93-6.
33. Wagner R, Straub ML, Souciet JL, Potier S, de Montigny J. New plasmid system to select for Saccharomyces cerevisiae purine-cytosine permease affinity mutants. J Bacteriol. 2001; 183: 4386-8.
34. Chapeland-Leclerc F, Bouchoux J, Goumar A, Chastin C, Villard J, Noël T. Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob Agents Chemother. 2005; 49: 3101-8.